5/27/20 was the worst day for our team since March 13th when almost every stock on the market was halted due to volatility. Our two largest positions, La Jolla Pharmaceuticals (Nasdaq: LJPC) and … [Read more...] about LJPC and BCRX Updates: 5/27/20
DelMar Pharmaceutical (NASDAQ: DMPI) Remains On Track Despite COVID-19 Crisis
Recap: Since November of 2019 MS Money Moves has been following DelMar Pharmaceuticals (Nasdaq: DMPI) closely through a number of key value inflection points. In my initial article I … [Read more...] about DelMar Pharmaceutical (NASDAQ: DMPI) Remains On Track Despite COVID-19 Crisis
How To Day Trade Stocks
Several of our community members have asked us about how to go about day-trading stocks. In this article I will outline our day-trading strategy using BCRX as an example. What To Look … [Read more...] about How To Day Trade Stocks
Quarterly Update, 1Q20: LJPC
In this article series I go over our core investments, their investment thesis, and new developments during the First Quarter of 2020 (1/1/20 to 3/31/20) starting with LJPC. La Jolla … [Read more...] about Quarterly Update, 1Q20: LJPC
Daily Trade Insights
Updated on 5/28/20Click here to read Chris Stang, PharmD's research on Zynerba Pharmaceuticals (Nasdaq: ZYNE) Click here for Sultan's update on DelMar Pharmaceuticals (Nasdaq: DMPI)Click here to read … [Read more...] about Daily Trade Insights
BioCryst Pharmaceuticals (Nasdaq: BCRX) Galidesivir for the Treatment of COVID-19
In a matter of months, a novel strain of coronavirus infamously known as COVID-19 has spiraled from a local outbreak in China into a global pandemic. To date, there have been 1.5M+ confirmed cases and … [Read more...] about BioCryst Pharmaceuticals (Nasdaq: BCRX) Galidesivir for the Treatment of COVID-19
BCRX Updates
With BCRX there are a number of positive features that make it an attractive investment at its current valuation (near 5-year lows; on track to have its second commercial asset approved this year), … [Read more...] about BCRX Updates
LJPC Price Action Explained (2/12/20)
Yesterday started out very promising for LJPC. Based on the early trading activity it seemed we would see a sustained breakout to $10+. Instead, the stock ran to a high of $9.38 followed by a gradual … [Read more...] about LJPC Price Action Explained (2/12/20)
Dario Health (Nasdaq: DRIO) is Poised For a Transformative Year in 2020
Dario Health (NASDAQ: DRIO) Rating: Strong Buy Investment SummaryTicker: DRIO (Last: $8.40)Market Cap: $60MAccumulate: $7-9Price Target: $16-20Timeframe: 0-24 weeks Investment … [Read more...] about Dario Health (Nasdaq: DRIO) is Poised For a Transformative Year in 2020
LJPC Update
Rating: BTFD (buy the effin dip) Since our initial coverage, the LJPC thesis has been unfolding according to plan. For a look back at the initial story, click here. With RSI approaching oversold … [Read more...] about LJPC Update
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Japanese
Portuguese
Russian
Spanish